The European Union s (EU s) Scientific Committee on Consumer Safety (SCCS) recently updated its notes of guidance (NoG) for cosmetics and cosmetic ingredient safety testing, emphasizing alternatives to animal testing, nanomaterials and more.
To embed, copy and paste the code into your website or blog:
In 2016, the Organization for Economic Cooperation and Development’s (OECD) Working Party on Manufactured Nanomaterials (WPMN) included the Advancing Adverse Outcome Pathway (AOP) Development for Nanomaterial Risk Assessment and Categorization (NanoAOP) project in its program of work. The objective of the project is to contribute to the future development and application of AOPs for manufactured nanomaterial regulatory decision making by following the principles established by the OECD Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST). OECD has published three reports presenting the outcomes of the project:
Advancing Adverse Outcome Pathway (AOP) Development for Nanomaterial Risk Assessment and Categorisation Part 2: Case Study on Tissue Injury: This report presents a case study focused on a specific key event in the inflammation pathway to analyze the empirical evidence and contribute to
Nanotechnology Now
Our NanoNews Digest Sponsors
Home > Nanotechnology Columns > Bergeson & Campbell, P.C. > OECD Publishes Reports on Outcome of Project on Advancing Adverse Outcome Pathway Development for Nanomaterial Risk Assessment and Categorization
Lynn L. Bergeson
Abstract:
In 2016, the Organization for Economic Cooperation and Development s (OECD) Working Party on Manufactured Nanomaterials (WPMN) included the Advancing Adverse Outcome Pathway (AOP) Development for Nanomaterial Risk Assessment and Categorization (NanoAOP) project in its program of work.
December 22nd, 2020
OECD Publishes Reports on Outcome of Project on Advancing Adverse Outcome Pathway Development for Nanomaterial Risk Assessment and Categorization
In 2016, the Organization for Economic Cooperation and Development s (OECD) Working Party on Manufactured Nanomaterials (WPMN) included the Advancing Adverse Outcome Pathway (AOP) Development for Nanomaterial Risk Assessment and Categorization (NanoAOP) pro